Immunic’s (IMUX) “Buy” Rating Reiterated at HC Wainwright

by · The Markets Daily

HC Wainwright reissued their buy rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. They currently have a $22.00 price objective on the stock.

A number of other research analysts also recently issued reports on the stock. Wedbush started coverage on shares of Immunic in a research report on Monday, August 17th. They issued an “outperform” rating and a $45.00 price target on the stock. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th. Wolfe Research initiated coverage on shares of Immunic in a research note on Friday, May 22nd. They set an “outperform” rating on the stock. B. Riley Financial cut their target price on shares of Immunic from $40.00 to $27.00 and set a “buy” rating on the stock in a report on Friday, May 22nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, August 26th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $47.25.

View Our Latest Stock Analysis on Immunic

Immunic Trading Down 3.5%

IMUX stock opened at $11.42 on Thursday. The stock’s 50 day simple moving average is $14.68 and its 200 day simple moving average is $13.08. Immunic has a 12-month low of $5.06 and a 12-month high of $17.43. The firm has a market cap of $155.77 million, a P/E ratio of -2.61 and a beta of 1.41.

Immunic (NASDAQ:IMUX – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.36. On average, research analysts forecast that Immunic will post -3.71 EPS for the current fiscal year.

Institutional Trading of Immunic

Large investors have recently modified their holdings of the company. Nantahala Capital Management LLC acquired a new stake in shares of Immunic in the fourth quarter valued at approximately $2,337,000. Millennium Management LLC raised its holdings in shares of Immunic by 544.6% during the fourth quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after buying an additional 2,888,829 shares during the last quarter. Avidity Partners Management LP boosted its position in shares of Immunic by 42.6% during the first quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock worth $7,436,000 after buying an additional 2,000,000 shares during the period. Laurion Capital Management LP boosted its position in shares of Immunic by 106.3% during the fourth quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock worth $2,072,000 after buying an additional 2,000,000 shares during the period. Finally, Renaissance Technologies LLC bought a new position in Immunic in the 1st quarter worth approximately $1,020,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

(Get Free Report)

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.

Featured Stories